References
- National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996; 276(23): 1907–15
- Astrup A, Lundsgaard C. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice. Exp Clin Endocrinol Diabetes 1998; 106 (Suppl 2): 29–34
- Lean MEJ, Powrie JK, Anderson AS, et al. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990; 7(3): 228–33
- Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 1999; 69(6): 1108–16
- Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 1998; 21(8): 1288–94
- Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281(3): 235–42
- Sjoström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352(9123): 167–72
- Apfelbaum M, Vague P, Ziegler O, et al. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999; 106(2): 179–84
- Abenheim L, Moride Y, Brenot F, et al, for the International Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335(9): 609–16
- Thomas SH, Butt AY, Corris PA. Appetite suppressants and primary pulmonary hypertension in the United Kingdom. Br Heart J 1995; 74(6): 660–3
- Simonneau G, Fartoukh M, Sitbon O, et al. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 1998; 114(3 Suppl): 195–9S
- Connolly HM, Crary JL, McGoon MD. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337(9): 581–8
- Goldstein DJ, Potvin JH. Long-term weight loss: the effect of pharmacologic agents. Am J Clin Nutr 1994; 60(5): 647–57
- Weintraub M. Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study. Clin Pharmacol Ther 1992; 51(5): 581–5, 642–6
- Munro JF, Maccuish AC, Wilson EM, et al. Comparison of continuous and intermittent anorectic therapy in obesity. BMJ 1968; 1: 352–4
- Van Gaal LF, Wauters MA, De Leeuw IH. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contributions to obesity treatment. Exp Clin Endocrinol Diabetes 1998; 106(Suppl 2): 35–40
- Lean ME. Sibutramine—a review of clinical efficacy. Int J Obes Relat Metab Disord 1997; (21 Suppl 1): 30–6S
- Levine LR, Enas GG, Thompson WL, et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. Int J Obes 1989; 13(5): 635–45
- Beckwith C. Ma huang and ephedrine in dietary supplements. The Pharmacist's Letter Mar 1999; 16
- Heymsfield SB, Allison DB, Vasselli JR, et al. Garcinia Cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA 1998; 280(18): 1596–600
- Badmaev V, Majeed M, Conte AA. Garcinia combogia for weight loss. (Letter) JAMA 1999; 282(3): 233–4
- Schaller JL. Garcinia Cambogia for weight loss. (Letter) JAMA 1999; 282(3): 234